Appointment · 21 October 2026
Voyager Therapeutics, Inc.
VYGR · Listed
Key facts
- How the CEO left
- Not specified
- Planned or abrupt
- Planned
- Successor
- Not stated
- Outgoing CEO stays as
- Not stated
- Signs it was forced
- None stated
- Other news alongside
- None
Read from the filing and press release by a language model (Google Gemini), told to use only that text. It can make mistakes; the quotes below are the source.
The announcement
Ms. Swartz is also expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D. as Chief Executive Officer of the Company following the anticipated receipt in the first quarter of 2027 of initial acute safety data in connection with its clinical trial of VY1706 in adults with early Alzheimer’s Disease.
Sentences matched by our CEO change rules, from the first filing. Read the 8-K on SEC EDGAR ↗
Share price reaction
The filing reached SEC EDGAR on 21 October 2026 at 12:07 New York time, during trading hours, so day 0 is that same day. Day 0 is marked by the vertical line.
| Window | VYGR | S&P 500 | Abnormal |
|---|---|---|---|
| Days 0 to +1 | −15.1% | −0.7% | −14.3% |
| Days 0 to +3 | −20.1% | −0.5% | −19.9% |
| 1 month (days 0 to +21)so far, 5 of 22 days | −21.0% | +0.1% | −21.5% |
| 3 months (days 0 to +63)so far, 5 of 64 days | −21.0% | +0.1% | −21.5% |
The abnormal return is the stock's return beyond what its usual relationship with the market (beta 1.29) predicts. A single stock's move can reflect other news on the same days, so it describes what happened rather than measuring the effect of the CEO change; averages across many events are on the Research design page as they are completed.
News coverage
No matching headlines found. Coverage is thinner for smaller companies.